WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals

Duración
June 2017 - September 2019
Coordinador
Alberto García-Basteiro
Financiadores
USAID / KNCV

This study is a parallel, two part, open label, individually randomized, pragmatic clinical trial to assess different alternatives to prevent tuberculosis (TB) among HIV-positive individuals. Part A compares a single round of weekly high dose rifapentine plus isoniazid for three months (3HP) to six months of daily isoniazid (6H). Part B compares periodic 3HP (p3HP) to a single round of 3HP.

This clinical trial aims to improve (shorten and simplify) currently available tools to prevent tuberculosis among HIV-positive individuals. The current recommendation is to provide single dose isoniazid daily during 6 months among HIV-positive individuals in whom TB disease has been ruled out. However, the implementation of this recommendation is limited in high burden countries, mostly due to adherence hurdles derived from such lengthy prophylaxis.

The study aims to enroll 4000 participants from three different countries: South Africa, Mozambique and Ethiopia. In Mozambique, the only participating site will be the Centro de Investigação em Saude de Manhiça (CISM).

Total funding

1.6 million Euros

Nuestro equipo

Principal Investigator

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

CARE

Linkage and retention in care following home-based HIV testing serosurveys in Manhiça District, Southern Mozambique

METRO

Measuring community prevalence among HIV exposed children in rural Southern Mozambique

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

www.mamahproject.net